Role of SNF5 in rheumatoid arthritis by upregulation of p16 and inactivation of JNK pathway

This study aims to explore the role and the possible underlying molecular mechanism of SNF5 in the pathogenesis of rheumatoid arthritis (RA). MH7A cells were respectively transfected with pc-SNF5 (pcDNA3.1 containing the Brg1 coding sequence), short hairpin RNA against SNF5 (shSNF5), and their negative controls (pcDNA3.1 and shNC). The alterations of SNF5 expression were assessed by qRT-PCR and western blot analysis. MTT assay, flow cytometry, and western blot analysis were performed to evaluate proliferation, apoptosis, and expression levels of p16 and JNK pathway associated proteins, respectively. Finally, the effect of SNF5 was verified in fibroblast-like synoviocytes (FLSs) obtained from a rat model with adjuvant-induced arthritis. Results showed that the expression of SNF5 was increased in the pc-SNF5 group (P < 0.05) while it was decreased in the shSNF5 group (P < 0.05). Afterwards, cell viability after transfection was reduced by SNF5 overexpression (P < 0.05, P < 0.01, or P < 0.001), whereas it was enhanced by SNF5 knockdown (P < 0.05 or P < 0.001). In terms of apoptosis, SNF5 overexpression promoted cell apoptosis (P < 0.01). The western blot analysis showed that the phosphorylated levels of proteins involved in the JNK pathway were downregulated by SNF5 overexpression while they were upregulated by SNF5 knockdown (P < 0.05, P < 0.01, or P < 0.001). However, the effect of SNF5 on the expression of p16 was the opposite. Finally, the effect of SNF5 was validated in murine FLSs. In conclusion, SNF5 suppresses proliferation and induces apoptosis of fibroblast-like cells through overexpression of p16 and suppression of the JNK pathway.

PDF

___

Barr RK, Bogoyevitch MA (2001). The c-Jun N-terminal protein kinase family of mitogen-activated protein kinases (JNK APKMs). Int J Biochem Cell B 33: 1047-1063.
Capsoni F, Ongari AM, Lonati C, Accetta R, Gatti S, Catania A (2015). Alpha-melanocyte-stimulating-hormone (α-MSH) modulates human chondrocyte activation induced by proinflammatory cytokines. BMC Musculoskelet Disord 16: 154.
Choi BY, Choi HS, Ko K, Cho YY, Zhu F, Kang BS, Ermakova SP, Ma WY, Bode AM, Dong Z (2005). The tumor suppressor P16(Ink4a) prevents cell transformation through inhibition of c-Jun phosphorylation and Ap-1 activity. Nat Struct Mol Biol 12: 699-707.
Choy E, Panayi G (2001). Cytokine pathways and joint inflammation in rheumatoid arthritis. New Engl J Med 344: 907-916.
Clapier CR, Cairns BR (2009). The biology of chromatin remodeling complexes. Annu Rev Biochem 78: 273-304.
Euskirchen GM, Auerbach RK, Davidov E, Gianoulis TA, Zhong G, Rozowsky J, Bhardwaj N, Gerstein MB, Snyder M (2011). Diverse roles and interactions of the Swi/Snf chromatin remodeling complex revealed using global approaches. PLoS Genet 7: 118-124.
Gresh L, Bourachot B, Reimann A, Guigas B, Fiette L, Garbay S, Muchardt C, Hue L, Pontoglio M, Yaniv M (2005). The Swi/Snf chromatin-remodeling complex subunit Snf5 is essential for hepatocyte differentiation. EMBO J 24: 3313-3324.
Han Z (2001). C-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J Clin Invest 108: 73-81.
Han Z, Boyle DL, Aupperle KR, Bennett B, Manning AM, Firestein GS (1999). Jun N-terminal kinase in rheumatoid arthritis. J Pharmacol Exp Ther 291: 124-130.
Johnson GL, Lapadat R (2002). Mitogen-activated protein kinase pathways mediated by Erk, Jnk, and P38 protein kinases. Science 298: 1911-1912.
Kadoch C, Crabtree GR (2015). Mammalian Swi/Snf chromatin remodeling complexes and cancer: mechanistic insights gained from human genomics. Sci Adv 1: e1500447.
Kusafuka T, Miao J, Yoneda A, Kuroda S, Fukuzawa M (2004). Novel germ-line deletion of SNF5/INI1/SMARCB1 gene in neonate presenting with congenital malignant rhabdoid tumor of kidney and brain primitive neuroectodermal tumor. Gene Chromosome Canc 40: 133-139.
Müllerladner U, Pap T, Gay RE, Neidhart M, Gay S (2005). Mechanisms of disease: the molecular and cellular basis of joint destruction in rheumatoid arthritis. Nature Clin Pract Rheum 1: 102-110.
Murakami Y, Mizoguchi F, Saito T, Miyasaka N, Kohsaka H (2012). p16INK4a exerts an anti-inflammatory effect through accelerated IRAK1 degradation in macrophages. J Immunol 189: 5066- 5072.
Nakayama H, Yaguchi T, Yoshiya S, Nishizaki T (2012). Resveratrol induces apoptosis Mh7a human rheumatoid arthritis synovial cells in a sirtuin 1-dependent manner. Rheumatol Int 32: 151- 157.
Narlikar G, Sundaramoorthy R, Owen-Hughes T (2013). Mechanisms and functions of ATP-dependent chromatinremodeling enzymes. Cell 154: 490-503.
Nasu K, Kohsaka H, Nonomura Y, Terada Y, Ito H, Hirokawa K, Miyasaka N (2001). adenoviral transfer of cyclin-dependent kinase inhibitor genes suppresses collagen-induced arthritis in mice. J Immunol 165: 7246-7252.
Nishida K, Komiyama T, Miyazawa SI, Shen ZN, Furumatsu T, Doi H, Yoshida A, Yamana J, Yamamura M, Ninomiya Y (2004). Histone deacetylase inhibitor suppression of autoantibodymediated arthritis in mice via regulation of p16INK4a and P21WAF1/Cip1 expression. Arthritis Rheum 50: 3365-3376.
Nonomura Y, Kohsaka H, Nasu K, Terada Y, Ikeda M, Miyasaka N (2001). Suppression of arthritis by forced expression of cyclindependent kinase inhibitor p21Cip1 gene into the joints. Int Immunol 13: 723-731.
Nonomura Y, Nagasaka K, Hagiyama H, Sekine C, Nanki T, Tamamori-Adachi M, Miyasaka N, Kohsaka H (2006). Direct modulation of rheumatoid inflammatory mediator expression in retinoblastoma protein-dependent and -independent pathways by cyclin-dependent kinase 4/6. Arthritis Rheum 54: 2074-2083.
Piecyk M, Anderson P (2001). Signal transduction in rheumatoid arthritis. Arthritis Res Ther 14: O38.
Ramirez-Carrozzi VR, Nazarian AA, Li CC, Gore SL, Sridharan R, Imbalzano AN, Smale ST (2006). Selective and antagonistic functions of Swi/Snf and Mi-2β nucleosome remodeling complexes during an inflammatory response. Gene Dev 20: 282-296.
Roberts CWM, Galusha SA, Mcmenamin ME, Fletcher CDM, Orkin SH (2000). Haploinsufficiency of Snf5 (integrase interactor 1) predisposes to malignant rhabdoid tumors in mice. P Natl Acad Sci USA 97: 13796-13800.
Roberts LJ (1998). New drugs for rheumatoid arthritis. Med Lett Drugs Ther 40: 2167-2179.
Sansam CG, Tamayo P, Subramanian A, Evans JA, Fillmore CM, Roberts CWM, Mesirov JP, Biegel JA, Isakoff MS, Pomeroy SL (2005). Inactivation of the Snf5 tumor suppressor stimulates cell cycle progression and cooperates with P53 loss in oncogenic transformation. P Natl Acad Sci USA 102: 17745-17750.
Sherr CJ, Roberts JM (1995). Inhibitors of mammalian G1 cyclindependent kinases. Gene Dev 9: 1149-1163.
Smolen JS, Steiner G (2003). Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discov 2: 2591-2602.
Taniguchi K, Kohsaka H, Inoue N, Terada Y, Ito H, Hirokawa K, Miyasaka N (1999). Induction of the P16INK4a senescence gene as a new therapeutic strategy for the treatment of rheumatoid arthritis. Nat Med 5: 760-767.
Tournier C, Hess P, Yang DD, Xu J, Turner TK, Nimnual A, Barsagi D, Jones SN, Flavell RA, Davis RJ (2000). Requirement of JNK for stress-induced activation of the cytochrome C-mediated death pathway. Science 288: 870-874.
Wei ZF, Jiao XL, Wang T, Lu Q, Xia YF, Wang ZT, Guo QL, Chou GX, Dai Y (2013). Norisoboldine alleviates joint destruction in rats with adjuvant-induced arthritis by reducing RANKL, IL-6, PGE2, and MMP-13 expression. Acta Pharm Sinic 34: 403-413.
Xu Y, Yan W, Chen X (2010). SNF5, a core component of the SWI/ SNF complex, is necessary for P53 expression and cell survival, in part through eIF4E. Oncogene 29: 4090-4100.